Hassle free Returns FREE Shipping on orders above 500/- Cash On Delivery

Support 0484 4080450 | support@curegarden.in

A new study talks about BCM-95(TM) curcumin’s effectiveness on depression

Posted on 26-12-16

BCM-95™ has been the subject of 13 published articles of which 8 cover clinical trials. It is known that BCM-95™ curcumin has greater bioavailability than 95 percent extract of turmeric and, in fact, has 7 to 10 times better absorption than ordinary curcumin.
A recently published clinical trial involving major depressive disorder (MDD) demonstrates that BCM-95™ curcumin had the same effects of the prescription drug fluoxetine (generic name for Prozac) but without the negative side-effects.
According to Dr. Ajay Goel, Baylor Research Institute and Charles A Samons Cancer Center, Baylor University Medical Center and study co-author, “It is a novel and surprising application for this natural medicine. People with depression have higher levels of inflammation in the brain. Also, people with depression have lower levels of neurogenesis in the brain, meaning they make fewer new brain cells than people with no history of depression. Curcumin is both a potent anti-inflammatory agent and a powerful stimulator for neurogenesis. A recent animal study was published on BCM-95™ curcumin compared to both fluoxetine and imipramine (an older class of antidepressant medications) and showed excellent results. We are excited to learn the effectiveness of BCM-95™ curcumin in a human study”.
It is known that depression is a worldwide health issue that leads to considerable disability. The administration of drugs is very costly — not to mention the associated adverse side-effects. And, for many individuals, drug therapy doesn’t remove all the symptoms.
This recent trial included three arms of 20 volunteers who had been diagnosed with major depressive disorder. These volunteers received either BCM-95™ curcumin (500 mg capsules twice daily); fluoxetine (20 mg daily) or a combination of BCM-95™ curcumin (twice daily) with fluoxetine (once daily). The Hamilton Rating Scale for Depression (HAM-D17) was used to evaluate these volunteers. The Hamilton Scale for Depression evaluates the severity of depression by looking at mood, guilt feelings, suicidal thoughts, sleeplessness, anxiety, agitation or motor retardation, weight loss and other somatic symptoms.
The researchers report that BCM-95™ curcumin was well tolerated and that patients who received both treatments (BCM-95™ curcumin and fluoxetine) received a higher HAM-D17 score. The combined therapy score was 77.8 percent, fluoxetine group scored 66.7 percent and the BCM-95™ curcumin group scored 62.5 percent. According to these researchers, these data were not statistically significant (P= 0.58) from one another, therefore, curcumin worked as well as the drug fluoxetine according to HAM-D17 score. This is the first human clinical evidence that curcumin (BCM-95™ curcumin) may be used as a therapy for patients with MDD without concurrent suicidal thoughts or other psychotic disorders.
*Published online in July 2013, “Efficacy and safety of curcumin in major depressive disorder”. A randomized controlled trial, Phytothrapy research by Sanmukhani, V Satodia, J Trived, T Patel, D Tiwar, B Panchal, A Goel and CB Tripathi.



Curegarden represents a dream. A dream of sharing a happier, healthier body and quality of life with the use of nature's best ingredients. Botanics, when extracted for their bioactive compounds, offer a most effective approach to improving well-being and quality of life. It is based on the belief that botanicals of the highest quality would have a positive effect — without any negative side effects — on people's health. Over the years,we have seen and experienced personally the wonderful benefits of these high quality botanical products and are delighted to share them with others.


Arjuna Natural Extracts Ltd is India’s leading manufacturer and exporter of standardized botanical extracts for pharmaceutical and nutraceutical industries for over two decades. With customers in around 40 countries, the company has close to 50 patents to its credit of which majority are commercialized globally. The company has R&D tie ups with international universities from Australia, US and Japan. The highly advanced R&D unit at Arjuna is a complete research facility for phytochemistry, pharmacokinetics, formulation and development, pre-clinical and clinical studies.